Control
Zansecimab (LY3127804) is an intravenous monoclonal antibody that targets Angiopoietin-2 (Ang-2), a key protein in vascular inflammation.
Jan 31 2022 |
et al., Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, doi:10.1177/11795484221119316 | Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19 |
| 36% higher mortality (p=0.58) and 70% higher combined mortality/intubation (p=0.28). RCT 95 hospitalized patients with COVID-19 pneumonia showing no significant differences with zansecimab (LY3127804, anti-Angiopoietin-2 antibody). | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.